ESR2 and urinary bladder carcinoma: More specifically, selective agonists for ERα (i.e., propyl-pyrazole-triol) and ERβ (i.e., diatylpropionitrile) increased the cell proliferation of ERα-positive/ERβ-positive bladder cancer lines, but not those expressing an ERα-siRNA and an ERβ-siRNA, respectively [50].